Premium
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer
Author(s) -
ARISTIDES M.,
VON DER MAASE H.,
ROBERTS T.,
BROWN A.,
KIELHORN A.,
BHALLA S.
Publication year - 2005
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2005.00521.x
Subject(s) - gemcitabine , medicine , toxicity , bladder cancer , urothelial cancer , vinblastine , cisplatin , oncology , chemotherapy , cancer , doxorubicin , methotrexate , cancer treatment
Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity. The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al. 2000). At present, the importance to patients of the toxicity of chemotherapy has not been widely studied. An earlier study in bladder cancer indicated that toxicity was an important determinant of treatment preference (Davey et al. 2000). A study of preferences for advanced bladder cancer therapy in the UK was proposed.